Ziagen News and Research

RSS

Retinal hyperspectral imaging shows promise for early Alzheimer's disease detection

Alzheimer's disease is the leading cause of dementia in the U.S., with approximately 5.4 million currently affected and an estimated 16 million by 2050.

11 Nov 2019

Severe hypersensitivity reactions to anti-HIV drug occur through autoimmune mechanism

Potentially severe hypersensitivity reactions to the anti-HIV drug abacavir occur through an autoimmune mechanism, resulting from the creation of drug-induced immunogens that are attacked by the body's immune system, according to a study published online by the journal AIDS, official journal of the International AIDS Society.

23 May 2012

Researchers identify new mechanism for drug-related autoimmune reactions

A team of researchers led by the U.S. Food and Drug Administration has discovered a new mechanism for identifying and understanding drug-related autoimmune reactions.

23 May 2012

NHGRI's new strategic plan to identify genetic bases of most single-gene disorders

A new strategic plan from an arm of the National Institutes of Health envisions scientists being able to identify genetic bases of most single-gene disorders and gaining new insights into multi-gene disorders in the next decade. This should lead to more accurate diagnoses, new drug targets and the development of practical treatments for many who today lack therapeutic options, according to the plan from the National Human Genome Research Institute (NHGRI).

14 Feb 2011

Shionogi-ViiV Healthcare initiates 572-Trii fixed-dose combination therapy study for HIV

Shionogi-ViiV Healthcare, LLC announced today that the first patient has entered the clinical study, SINGLE (ING114467), designed to support a new fixed-dose combination (FDC) therapy for the treatment of HIV.

3 Feb 2011

Genocea announces close of $35 million Series B venture financing round

Genocea Biosciences Inc., a vaccine discovery and development company pioneering a new class of T cell-based vaccines, today announced that it has closed a $35 million Series B round of venture financing, with new investors Johnson & Johnson Development Corporation (JJDC), Skyline Ventures and MP Healthcare Venture Management, Inc. (MPH) joining existing investors Polaris Venture Partners, Lux Capital Management, SR One, Cycad Group, Auriga Partners and Morningside Ventures.

3 Jan 2011

Matrix's NDA for Abacavir Sulfate receives tentative FDA approval under PEPFAR

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Abacavir Sulfate Tablets, 60 mg. The NDA is based on the reference listed drug Ziagen® by ViiV Healthcare.

7 Dec 2010

Pathway Genomics' personal Genetic Health Report now available

Pathway Genomics Inc., a U.S. based genetic testing company, announced the immediate availability of its personal Genetic Health Report. This customized and innovative personal genetic health report contains information on more than 70 health conditions, including pharmacogenetics (prescription medication response), propensity for complex disease, and carrier status (pre-pregnancy health).

17 Mar 2010

ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI

At the 17th Conference on Retroviruses and Opportunistic Infections (CROI), ViiV Healthcare presented new data across its broad range of investigational and current medicines for the treatment of HIV/AIDS. Highlighted data at the conference included an oral presentation on the investigational integrase inhibitor, S/GSK1349572, as well as data presentations on SELZENTRY® (maraviroc) and EPZICOM® (abacavir/lamivudine).

24 Feb 2010

GlaxoSmithKline pledges $97 million investment in AIDS drugs for Africa, allows South African drugmaker to produce generic second-line treatment

GlaxoSmithKline (GSK) on Tuesday announced plans to invest $97 million over 10 years "to improve research, development and access to AIDS drugs in Africa," Reuters reports.

15 Jul 2009